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The risk of relapse after successful repigmentation in vitiligo is estimated to 40% within the first year. It has been
shown in atopic dermatitis that continuous low-level use of topical corticosteroids and calcineurin inhibitors in
previously affected skin can prevent new flares. We hypothesized that a twice-weekly application of 0.1%
tacrolimus ointment might be effective for maintaining repigmentation in therapeutically repigmented lesions of
vitiligo patients. After randomization, sixteen patients with 31 patches were assigned to the placebo group and 19
patients with 41 patches were assigned to the tacrolimus group. In the intention-to-treat analysis, 48.4% of lesions
showed depigmentation in the placebo group, whereas 26.8% did in the tacrolimus group (P¼ 0.059). The
intention-to-treat results did not remain significant after adjustment for within-patient clustering, odds ratio (OR)
2.55; 95% confidence interval (CI; 0.65–9.97); P¼ 0.1765. The per-protocol analysis (n¼ 56) showed that 40% of
lesions had some depigmentation in the placebo group, whereas only 9.7% did in the tacrolimus group
(P¼ 0.0075). The per-protocol results remained significant after adjustment for within-patient clustering: OR 6.22;
95% CI (1.48–26.12); P¼ 0.0299. Our study shows that twice-weekly application of 0.1% tacrolimus ointment
is effective in preventing the depigmentation of vitiligo patches that have been previously successfully
repigmented.
Journal of Investigative Dermatology (2015) 135, 970–974; doi:10.1038/jid.2014.527; published online 15 January 2015
INTRODUCTION
Vitiligo is an acquired depigmentation of the skin and some-
times hair follicle affecting 0.5% to 1% of the world’s
population. The pathophysiology is complex and involves
several possible cellular mechanisms. There is now strong
evidence for a role of both oxidative stress and immune
systems in genetically predisposed individuals (Passeron and
Ortonne, 2012). Although there is no cure for vitiligo,
treatments such as excimer light, topical tacrolimus or pime-
crolimus, and combination approaches (with phototherapy
and topical steroids or calcineurin inhibitors) can provide
cosmetically acceptable repigmentation (475%), in particular
on the face and neck (Ostovari et al., 2004; Passeron et al.,
2004; Whitton et al., 2010; Felsten et al., 2011; Taieb et al.,
2013; Ezzedine et al.). However, one of the major concerns in
patients who achieve repigmentation of vitiligo lesions is the
risk of relapse estimated to be almost 40% within the first year
after stopping treatment (Nicolaidou et al., 2007). To date,
there is no treatment to prevent relapses. Of note, the chronic
and unpredictable course of the disease has a strong impact
on the quality of life of affected individuals (Parsad et al.,
2003). It has been shown in atopic dermatitis that between
flares the skin has a subclinical inflammatory infiltrate.
Proactive treatment consisting of continuous low-level use of
topical anti-inflammatory agents (topical steroids or topical
calcineurin inhibitors) to previously affected skin areas has
shown to be effective for preventing new flares of atopic
dermatitis (Schmitt et al., 2011). We therefore hypothesized
that a twice-weekly application of 0.1% tacrolimus ointment
might be effective for maintaining repigmentation and
preventing relapses of previously repigmented lesions in
vitiligo patients.
RESULTS
A total of 78 consecutive patients from the clinics of vitiligo of
Bordeaux and Nice university hospitals, who received treat-
ment for vitiligo, were assessed for eligibility. Of these, 37
came back for routine follow-up visit with a repigmentation
rate of 475% in at least one lesion. For each patient, one to
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four lesions had successfully repigmented. As two patients
denied participating in this maintenance therapy study,
35 patients with 72 lesions were finally enrolled. Sixteen
patients with 31 patches were assigned to undergo placebo
and 19 with 41 patches were assigned to undergo topical
tacrolimus. Five patients were lost to follow-up. The flow
diagram of the study is summarized in Figure 1, and localiza-
tions of the lesions and the treatments that allowed the initial
repigmentation rate of more than 75% are presented in
Figure 2. Characteristics of patients and clinical data about
their vitiligo were comparable at baseline. They are presented
in Table 1 and Supplementary Table 1 online.
In the intention-to-treat (ITT) analysis (n¼ 72), 48.4% of
lesions showed some depigmentation in the placebo group,
whereas 26.8% did in the tacrolimus group (P¼ 0.059). In per-
protocol analysis (n¼56), we observed that 40.0% of lesions
showed some depigmentation in the placebo group, whereas
only 9.7% did in the tacrolimus group (P¼0.0075; Figure 3).
A depigmentation superior to 50% was observed in 12% of
the lesions in the placebo group and 0% in the tacrolimus
group (Figure 3).
Accounting for within-patient clustering in generalized
estimation equations models resulted in the ITT analysis, in
a nonsignificant association, OR 2.55; 95% CI (0.65–9.97);
P¼0.1765, whereas in per-protocol analysis tacrolimus main-
tenance therapy was significantly associated with lesions
pigmentation, OR 6.22; 95% CI (1.48–26.12); P¼0.0299,
consistently with previous results.
The localizations of treated lesions in the placebo group are
face and neck 86% and rest of the body 14%. In the face and
neck group, 40% showed a depigmentation and 60% no
depigmentation. In the rest of the body group, 46% showed a
depigmentation and 54% no depigmentation. The localiza-
tions of treated lesions in the tacrolimus group are face and
neck 73% and rest of the body 27%. In the face and neck
group, 4% showed a depigmentation and 96% no depigmen-
tation. In the rest of the body group, 22% showed a
depigmentation and 78% no depigmentation (Supplementary
Figure 1A online). This clearly shows the benefits of a twice-
weekly tacrolimus maintenance therapy, especially in face/
neck areas but also on the rest of the body. The depigmenta-
tion rate according to lesions that were initially repigmented
following tacrolimus treatment to those that repigmented with
any other treatment is reported in Supplementary Figure 1B
online. Further adjustment of the association between depig-
mentation and treatment use on these parameters, lesion
localization, and treatment modality used to repigment the
lesion did not change the results of the univariate models,OR
2.59; 95% CI (0.62–10.79), P¼ 0.1909 and OR 6.84, 95% CI
(1.23–38.10), P¼0.028, respectively, in the ITT and per-
protocol analyses.
The Physician Global Assessment (PGA) score showed, in
the placebo and tacrolimus groups, respectively, depigmenta-
tion in 48.2% versus 10.4%, no change in 40.7% versuss
58.6%, and repigmentation in 11.1% versus 31% of the
lesions (P¼ 0.0053).
78 patients assessed for eligibility
41 not meeting inclusion criteria
37 had at least one lesion with repigmentation>75%
2 refused to participate to 
the maintenance therapy
35 patients underwent
randomization
19 were assigned to 
undergo tacrolimus
16 were assigned to 
undergo placebo
2 refused to continue
for professional 
reason
19 patients were included 
in ITT main analysis
16 patients were included 
in ITT main analysis
2 were lost to follow up1 was lost to follow up
Figure 1. Flow diagram of the study.
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The quality of life slightly improved in both groups from
4.79 (± 3.58) to 3.54 (±2.91) in the tacrolimus group versus
6.48 (±2.80) to 4.59 (±3.53) in the placebo group,
P¼0.6112. Four patients (three in the tacrolimus group and
one in the placebo group) reported side effects with mild and
transient erythema, stinging and burning sensations that did
not require any specific intervention. In all cases, the treat-
ment could be continued.
DISCUSSION
Our results show that a maintenance treatment using twice-
weekly applications of tacrolimus 0.1% can reduce the
recurrences of previously repigmented vitiligo lesions. In
atopic dermatitis, both topical steroids and tacrolimus oint-
ment were shown to be effective for preventing the relapses,
but a meta-analysis suggests that topical steroids might be the
more effective (Schmitt et al., 2011). In vitiligo, topical steroids
and tacrolimus ointment were shown to be as effective for
repigmenting the lesions, but side effects were fewer with
tacrolimus, especially on facial lesions (Lepe et al., 2003). We
thus decided to use tacrolimus for this study. However, it
might be hypothesized that twice-weekly applications of
topical steroids could also be effective for the maintenance
therapy in vitiligo. The low frequencies of the applications and
the absence of the need for concomitant sun or UV exposure
facilitated a good compliance in both groups. In atopic
dermatitis, some authors proposed 2 or 3 consecutive days
for convenience of the patients so they can do a ‘week-end’
therapy. The rationale of using tacrolimus twice a week is to
inhibit the low-grade immune reaction against melanocytes,
and to this respect it sounds more relevant to us to apply the
Face
8%
7%
6%
4%
75% 66%
3%
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14%11%
UVB
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pUVA
Topical corticoste roids
Topical tacrolimus
Other
Neck
Upper limb
Lower limb
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Figure 2. Localization of the lesions and therapies that allow their repigmentation. (a) Description of treated areas. (b) Treatments that allowed the repigmentation
before the patients entered the study.
Table 1. Characteristics of the population
Placebo
group
(n¼ 16)
Tacrolimus
0.1% group
(n¼19)
n % n %
Sex 16 19
Male 10 62.5 11 57.9
Female 6 37.5 8 42.1
Age (years) median
(interquartile range)
16 43.0 (38.0–46.5) 19 44.0 (33.0–52.0)
Skin type
II 0 0.0 3 15.8
III 11 68.8 13 68.4
IV 4 25.0 2 10.5
V 1 6.2 0 0.0
VI 0 0.0 1 5.3
Age at diagnosis 16 32.8 (17.0–40.8) 19 32.4 (25.2–43.2)
Previous repigmentation
episodes, n (%)
10 62.5 10 52.6
Under treatment 4 40.0 7 70.0
After sun exposure 6 60.0 3 30.0
Type of repigmentation
Marginal 6 37.5 6 31.6
Perifollicular 7 43.8 7 36.8
Both 3 18.7 6 31.6
Koebner’s phenomenon 6 37.5 6 31.6
Halo nevi 0 0.0 4 21.1
Vitiligo activity, n (%)
Active vitiligo 7 43.8 6 31.6
Stable vitiligo 9 56.2 13 68.4
Season of inclusion, n (%)
Winter 14 87.5 16 84.2
Summer 2 12.5 3 15.8
Associated auto-immune
disorder, n (%)
2 12.5 4 21.0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Placebo Tacrolim us 0.1%
90.30%
60.00%
28.00%
12.00% 9.70%
0%
Depigmentation >50%
Depigmentation <50%
No depigmentation
Figure 3. Depigmentation category.
M Cavalie´ et al.
Maintenance Therapy for Vitiligo
972 Journal of Investigative Dermatology (2015), Volume 135
treatment at more regular intervals. However, we cannot
assess whether this treatment schedule is optimal or not.
Further studies will have to determine whether other protocols
would be able to achieve even better results.
A limitation of this study is the number of patients lost to
follow-up. Unfortunately, four out of the five patients lost to
follow-up were in the tacrolimus group, and thus this had a
strong impact on the ITT results as the imputation performed
was considered a failure in the treatment of all lesions of
patients lost to follow-up. However, two patients in the
tacrolimus group withdrew from the study for professional
reasons and not for reasons linked to the treatment arm,
minimizing the risk of bias induced by study withdrawal
specifically associated with a treatment regimen. Neverthe-
less, even with such an imputation, in the ITT analysis three-
fourths of the lesions remained stable or continued to repig-
ment in the tacrolimus group as compared with only 52% in
the placebo group.
The results showed no significant variation in the Derma-
tology Life Quality Index in both groups. This is explained by
the fact that even though their treated lesions did not recur,
most of the patients still have several other stable vitiligo
lesions that continue to alter their quality of life.
A potential bias could have resulted from the differences
between groups in terms of vitiligo activity and season of
inclusion (with a potential beneficial action of sun exposure).
However, the two groups were comparable at baseline for
these parameters. Localization of the lesions has been shown
for affecting the response to repigmenting therapies in vitiligo
(Ostovari et al., 2004; Passeron et al., 2004). We did not
include very resistant areas such as hands and feet in either the
placebo or the tacrolimus group. However, face and neck are
known usually to have the best response rate. It is confirmed
here as more than three out of four of the lesions that were
initially repigmented, and thus included in the study, were
located on these localizations. Also, maintenance therapy
appeared to be more effective to maintain pigmentation on
face and neck as compared with the rest of the body (96% and
78% of the lesions treated, respectively). Hence, one could
have thought that a potential limitation arose from the fact
that the modality of the treatment that allowed for initial
repigmentation (i.e, tacrolimus or not) may have influenced
the response to the tacrolimus maintenance therapy. Hence,
as these parameters were potential important ones to account
for, in despite of randomization, we adjusted our analyses on
these variables. We observed no association of these
parameters (localization and treatment that allowed the
repigmentation) with the pigmentation outcome making very
unlikely their impact on our results. Thus, as the success rate
of maintenance therapy is independent of the modality of the
initial treatment, clinicians may choose to use this main-
tenance therapy regardless of whether topical tacrolimus,
topical steroids, or phototherapy was used for initial
treatment. However, further studies would be warranted to
determine formally whether localization influences or not the
efficacy of the maintenance therapy.
The relapse rate of 40% observed in the present study is
consistent with that reported in the literature (Nicolaidou
et al., 2007). Although the aim of the study was the main-
tenance of the repigmentation, we observed that one-third of
the lesions completed their repigmentation under twice-
weekly tacrolimus maintenance treatment, as the PGA score
shows. This suggests that tacrolimus 0.1% applied twice
weekly can achieve ongoing repigmentation in addition to
prevent the depigmentation. Interestingly, we observed that
four patients who completed the study and who did not have
recurrences during the study period had depigmentation
within the six months following the end of their partici-
pation. After the unblinding procedure, we noticed that all
of these four patients belonged to the tacrolimus group. This is
in favor of the effectiveness of tacrolimus for preventing
depigmentation as its discontinuation resulted, at least in
some patients, in a depigmentation.
Taken together, our data show that twice-weekly applica-
tion of 0.1% tacrolimus ointment is effective in preventing the
depigmentation of vitiligo patches that have been previously
successfully repigmented. Taking into account the data gath-
ered for atopic dermatitis, the effectiveness of such a main-
tenance approach in vitiligo suggests that a low-grade of
inflammation might also be observed in vitiligo lesions and be
responsible for the recurrences. This hypothesis is supported
by transcriptional analysis of non-depigmented skin of vitiligo
patients that also shows low-level of inflammation in these
areas compared with healthy controls (personal data, manu-
script in preparation).
These results have a strong implication in terms of daily care
of vitiligo patients. Further studies should determine the
optimal topical therapy and schedule of applications along
with the duration of such a maintenance treatment.
MATERIALS AND METHODS
Type of study
We conducted a bi-centric prospective randomized double-blind
placebo-controlled study. Prior to any procedures, the investigation
was approved by the local ethics committee and was registered at
the US National Institutes of Health Clinical Trial Register
(NCT01841008). Patients provided written informed consent before
randomization.
Settings
Departments of Dermatology of Nice and Bordeaux University
Hospitals between December 2011 and October 2013.
Patients
We recruited in a consecutive manner, patients with vitiligo for
whom lesions had been successfully treated (at least 75% of
repigmentation). Exclusion criteria were segmental vitiligo, sponta-
neous repigmentation, and contraindication to the use of topical
tacrolimus. For each patient, all the lesions that achieved at least 75%
of repigmentation were included.
Randomization
Patients were randomly assigned, in a 1:1 ratio, to either tacrolimus
ointment 0.1% or placebo (centralized randomization at methodolo-
gical center). All the patient’ lesions included in the study were
treated accordingly to the patient randomization arm.
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Interventions
After repigmentation, patients were immediately (or within a max-
imum of 2 weeks) transitioned to the maintenance protocol. Patients
had to apply twice weekly, in non-consecutive days, the ointment on
the repigmented areas over 24 weeks. If a patient has more than one
lesion to treat, all his lesions received the same product. We choose
to randomize by patient and not by lesions to be able to assess the
effect on the quality of life at the end of the study and to avoid any
confusion or misuse by the patient during the 6-month study
duration.
Evaluation
The efficacy of the treatment was evaluated on standardized pictures
with direct light and Wood lamp by two physicians blinded to
treatment received. They made a comparative evaluation of the
previously repigmented areas. The main criteria of evaluation was
the level of depigmentation assessed in three categories (0: no
depigmentation compared with the initial picture; 1: o50% depig-
mentation compared with the initial picture; 2: 450% depigmenta-
tion compared with the initial picture). In addition, PGA assessed the
evolution of vitiligo between initial and final pictures in three
categories: stable; repigmentation, and depigmentation. For depig-
mentation assessment and PGA, in case of discordance, a third
evaluation blinded to previous evaluations was asked to perform the
definitive evaluation. The quality of life was assessed using the
Dermatology Life Quality Index score. Evaluation was performed at
maintenance therapy initiation and at M6 (end of the study). Data
were collected using a standardized questionnaire, followed by a
complete clinical examination. Data on age, sex, skin type, age at the
diagnosis of vitiligo, family history of vitiligo, associated auto-immune
disorders including thyroiditis, Koebner phenomenon, episodes of
repigmentation in the past, localizations treated, treatment that
allowed to achieved the repigmentation, and activity of the vitiligo
were collected. The vitiligo was considered as active if there were
modifications of lesions or appearance of new ones in the past 3
months.
Sample size calculation
On the basis of the literature, we anticipated a depigmentation rate of
40% in the placebo group (Nicolaidou et al., 2007). Assuming an
expected depigmentation rate of 10% in the tacrolimus group, with a
80% power and 5% type I error, we calculated that 23 lesions by arm
were needed. Taking into account 10% of lost to follow-up, we
decided to include at least 52 lesions. According to the design of our
study, all the patches of a patient were treated in the same arm. We
assumed that, in a low hypothesis, around one-third of the selected
patients would present two lesions that achieved 75% of repigmen-
tation, and hence would be eligible for the study, and the others one
lesion. We then estimated the number of patients to include around
36 (21 patients with 1 lesion and 15 patients with 2 lesions, resulting
in a total of 52 lesions).
Statistical analyses
Analysis of the primary objective was performed on the ITT principle
in all patients who underwent randomization. Missing values were
imputed as failure to the treatment considering lost to follow-up
patients as having had relapse of their vitiligo. In the analyses, the
principal outcome, depigmentation, was considered as binary,
regardless of the percentage. A per-protocol analysis was also
performed considering only patients who completed the entire study
without violation to the protocol.
First, we compared the rate of depigmentation between treatment
groups, with the lesion as the statistical unit, using the w2 test. Then, to
account for within-patient clustering, we reanalyzed the data using
generalized estimation equations logistic models. Additional adjust-
ment of these models on the localizations treated (head and neck vs.
others) and the treatment that allowed to achieve the repigmentation
(tacrolimus yes/no) was performed.
We used the w2 test to compare PGA score between the groups and
an analysis of covariance to study the quality of life allowing
adjusting the analysis on the baseline value of the Dermatology Life
Quality Index score.
Two-sided P-valueso0.05 were considered statistically significant.
Statistical analyses were performed using SAS version 9.1 software
(SAS institute, Cary, NC).
CONFLICT OF INTEREST
Astellas provided research grant for this study.
ACKNOWLEDGMENTS
We thank Coralie Roger for data management.
Disclaimer
The sponsor had no role in the collection, interpretation and analysis of the
data, and in the drafting or the revision of the manuscript.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Ezzedine K, Eleftheriadou V, Whitton M et al. Vitiligo. Lancet (in press)
Felsten LM, Alikhan A, Petronic-Rosic V (2011) Vitiligo: a comprehensive
overview part II: treatment options and approach to treatment. J Am Acad
Dermatol 65:493–514
Lepe V, Moncada B, Castanedo-Cazares JP et al. (2003) A double-blind
randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment
of childhood vitiligo. Arch Dermatol 139:581–5
Nicolaidou E, Antoniou C, Stratigos AJ et al. (2007) Efficacy, predictors of
response, and long-term follow-up in patients with vitiligo treated with
narrowband UVB phototherapy. J Am Acad Dermatol 56:274–8
Ostovari N, Passeron T, Zakaria W et al. (2004) Treatment of vitiligo by 308-
nm excimer laser: an evaluation of variables affecting treatment response.
Lasers Surg Med 35:152–6
Parsad D, Dogra S, Kanwar AJ (2003) Quality of life in patients with vitiligo.
Health Qual Life Outcomes 1:58
Passeron T, Ortonne JP (2012) Activation of the unfolded protein response in
vitiligo: the missing link? J Invest Dermatol 132:2502–4
Passeron T, Ostovari N, Zakaria W et al. (2004) Topical tacrolimus and the
308-nm excimer laser: a synergistic combination for the treatment of
vitiligo. Arch Dermatol 140:1065–9
Schmitt J, von Kobyletzki L, Svensson A et al. (2011) Efficacy and tolerability of
proactive treatment with topical corticosteroids and calcineurin inhibitors
for atopic eczema: systematic review and meta-analysis of randomized
controlled trials. Br J Dermatol 164:415–28
Taieb A, Alomar A, Bohm M et al. (2013) Guidelines for the management of
vitiligo: the European Dermatology Forum consensus. Br J Dermatol
168:5–19
Whitton ME, Pinart M, Batchelor J et al. (2010) Interventions for vitiligo.
Cochrane Database Syst Rev CD003263
M Cavalie´ et al.
Maintenance Therapy for Vitiligo
974 Journal of Investigative Dermatology (2015), Volume 135
